CA2496272A1 - Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer - Google Patents

Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer Download PDF

Info

Publication number
CA2496272A1
CA2496272A1 CA002496272A CA2496272A CA2496272A1 CA 2496272 A1 CA2496272 A1 CA 2496272A1 CA 002496272 A CA002496272 A CA 002496272A CA 2496272 A CA2496272 A CA 2496272A CA 2496272 A1 CA2496272 A1 CA 2496272A1
Authority
CA
Canada
Prior art keywords
marker
expression
patient
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496272A
Other languages
English (en)
French (fr)
Inventor
John E. Monahan
Xumei Zhao
Yan Chen
Karen Glatt
Shubhangi Kamatkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2496272A1 publication Critical patent/CA2496272A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CA002496272A 2002-08-20 2003-08-20 Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer Abandoned CA2496272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40477002P 2002-08-20 2002-08-20
US60/404,770 2002-08-20
PCT/US2003/026184 WO2004018999A2 (en) 2002-08-20 2003-08-20 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Publications (1)

Publication Number Publication Date
CA2496272A1 true CA2496272A1 (en) 2004-03-04

Family

ID=31946760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002496272A Abandoned CA2496272A1 (en) 2002-08-20 2003-08-20 Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer

Country Status (9)

Country Link
US (3) US7361511B2 (enExample)
EP (6) EP2311978A1 (enExample)
JP (2) JP2006514823A (enExample)
KR (1) KR20050058407A (enExample)
CN (2) CN101044247B (enExample)
AT (1) ATE519862T1 (enExample)
AU (1) AU2003265556A1 (enExample)
CA (1) CA2496272A1 (enExample)
WO (1) WO2004018999A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
KR20050058407A (ko) * 2002-08-20 2005-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
AU2003278112A1 (en) * 2002-10-18 2004-05-04 Silence Therapeutics Ag Factor involved in metastasis and uses thereof
DE602005009702D1 (de) * 2004-07-16 2008-10-23 Oncomethylome Sciences S A Esr1 und gebärmutterhalskrebs
KR100939274B1 (ko) 2004-08-16 2010-01-29 쿠아크 파마수티칼스 인코퍼레이티드 알티피801 억제제의 치료적 용도
JP2009508493A (ja) 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
AT502722B8 (de) * 2005-10-31 2009-08-15 Bmt Medizinische Forschung Und Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
AU2006332806B2 (en) * 2005-12-30 2012-03-15 Ventana Medical Systems, Inc. Na+, K+-ATPase expression in cervical dysplasia and cancer
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc THERAPEUTIC USES OF RTP801L INHIBITORS
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
JP5526378B2 (ja) * 2009-03-05 2014-06-18 国立大学法人山口大学 子宮頸癌の検出方法
KR20120034593A (ko) * 2009-03-09 2012-04-12 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 위암 진단용 단백질 마커의 동정
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
CN102372773B (zh) 2010-08-11 2013-06-05 中国科学院生物物理研究所 人膀胱癌肿瘤标志物及其抗体和应用
MX347611B (es) 2011-06-19 2017-05-04 Abogen Inc Dispositivos, soluciones y metodos para recoleccion de muestras.
US9804160B2 (en) 2011-09-28 2017-10-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein-protein interaction as biomarkers
JP5876359B2 (ja) * 2012-03-30 2016-03-02 シスメックス株式会社 癌化情報提供方法および癌化情報提供装置
US20160187341A1 (en) * 2013-08-08 2016-06-30 The Research Foundation For The State University Of New York Keratins as biomarkers for cervical cancer and survival
CN114965989A (zh) 2015-02-09 2022-08-30 Dna吉诺特克股份有限公司 用于采集相关应用、分析和诊断的样本的设备、溶液和方法
SG11201708360TA (en) * 2015-04-13 2017-11-29 Aduro Biotech Inc Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
HK1250731A1 (zh) 2015-04-13 2019-01-11 艾杜罗生物科技公司 用於治疗癌症的免疫原性融合蛋白
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
CN109198732A (zh) * 2018-08-20 2019-01-15 苏州晞光生物科技有限公司 一种智能化可穿戴检测人体分泌物的服装及测试方法
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992012236A1 (en) * 1991-01-11 1992-07-23 The Regents Of The University Of California A NOVEL INTEGRIN β SUBUNIT AND USES THEREOF
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6033862A (en) 1996-10-30 2000-03-07 Tokuyama Corporation Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications
EP1019503A4 (en) * 1997-08-06 2003-04-23 Millennium Pharm Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES TANGO-71, TANGO-73, TANGO-74, TANGO-76 AND TANGO-83
CN1282422A (zh) * 1997-10-21 2001-01-31 癌症研究行动技术有限公司 对细胞生长异常的测定
WO2001042792A2 (en) 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins
AU2074201A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU750296B2 (en) * 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
GB2364921A (en) * 2000-07-18 2002-02-13 Collinson Jones Anthony Golf ball cleaning apparatus
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
AUPQ901700A0 (en) * 2000-07-26 2000-08-17 National Cancer Centre Of Singapore Pte Ltd Molecular markers
US7105293B2 (en) * 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20050058407A (ko) * 2002-08-20 2005-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
KR20080075045A (ko) * 2004-03-24 2008-08-13 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물

Also Published As

Publication number Publication date
US20120264625A1 (en) 2012-10-18
CN102220423A (zh) 2011-10-19
AU2003265556A8 (en) 2004-03-11
WO2004018999A3 (en) 2005-06-30
EP1565581A2 (en) 2005-08-24
EP1565581B1 (en) 2011-08-10
JP2006514823A (ja) 2006-05-18
ATE519862T1 (de) 2011-08-15
KR20050058407A (ko) 2005-06-16
US20080286781A1 (en) 2008-11-20
EP2314716A1 (en) 2011-04-27
CN101044247B (zh) 2011-06-22
AU2003265556A1 (en) 2004-03-11
CN101044247A (zh) 2007-09-26
EP1565581A4 (en) 2008-01-02
US20050037010A1 (en) 2005-02-17
EP2311980A1 (en) 2011-04-20
EP2311979A1 (en) 2011-04-20
WO2004018999A2 (en) 2004-03-04
EP2311978A1 (en) 2011-04-20
JP2011036247A (ja) 2011-02-24
US7361511B2 (en) 2008-04-22
EP2305836A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
CA2496272A1 (en) Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US8062892B2 (en) Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US20100075325A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003004989A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003009814A2 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2002071928A2 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2001070979A2 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2003050243A2 (en) Novel genes encoding colon cancer antigens
US20160326591A1 (en) Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
CA2541804A1 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1784511A2 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140820